Wu Tai-xiang, Liu Guan-jian, Zhang Ming-min, Wang Qin, Ni Juan, Wei Jia-fu, Zhou Li-kun, Duan Xin, Chen Xiao-yan, Zheng Jie, Qiao Jie-qi
Department of Clinical Epidemiology, Huaxi Hospital, Sichuan University, Sichuan 610041, China.
Zhonghua Yi Xue Za Zhi. 2003 Jul 25;83(14):1219-24.
To assess the benefits and harms of artemisinin-type compounds for preventing schistosomiasis.
The quality of included randomised controlled trials with the people at risk of contacting schistosomiasis were evaluated and Meta-analysis was conducted.
We found ten randomised controlled trials relating to our question. Of them, four trials were multi-centre studies, others were single centre studies. Numbers of participants in the trials ranged from 318 to 5,098, total 12,829. The total OR of 0.11 (95% CI 0.06 to 0.21) indicated that those who were administrated artemisinin-type compounds were significantly less infected with Schistosoma japonica than those who were administrated placebo.
Artemisinin-type compounds are effective drug for preventing Schistosomiasis japonica infection. Fifteen days interval schemes of artesunate and artemether be considered preferable to seven days interval scheme and were associated with very few side effects. More high quality controlled trials are required for assessing which scheme is the better. These studies should be large.
评估青蒿素类化合物预防血吸虫病的利弊。
对纳入的针对有感染血吸虫病风险人群的随机对照试验质量进行评估，并进行Meta分析。
我们找到了10项与我们的问题相关的随机对照试验。其中，4项试验为多中心研究，其他为单中心研究。试验中的参与者人数从318人到5098人不等，总计12829人。总OR值为0.11（95%CI为0.06至0.21），表明服用青蒿素类化合物的人感染日本血吸虫的几率明显低于服用安慰剂的人。
青蒿素类化合物是预防日本血吸虫感染的有效药物。青蒿琥酯和蒿甲醚的15天间隔方案被认为优于7天间隔方案，且副作用极少。需要更多高质量的对照试验来评估哪种方案更好。这些研究应该规模较大。
